Yeast models of Parkinson's disease-associated molecular pathologies

Current Opinion in Genetics and Development

Volumn 44, Issue , 2017, Pages 74-83

  Tenreiro, Sandra ^a   Franssens, Vanessa ^b   Winderickx, Joris ^b   Outeiro, Tiago Fleming ^a,c  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BENZIMIDAZOLE DERIVATIVE; BETA SYNUCLEIN; CYCLOPEPTIDE; GAMMA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; N ARYL BENZIMIDAZOLE; PARKIN; SYNPHILIN 1; UNCLASSIFIED DRUG;

ATP13A2 GENE; AUTOSOMAL DOMINANT DISORDER; COPY NUMBER VARIATION; DISEASE MODEL; DRUG DEVELOPMENT; EIF4G1 GENE; ENDOPLASMIC RETICULUM; EPIGENETICS; FUNGAL GENE; FUNGAL STRAIN; GENE; GENE MUTATION; GOLGI COMPLEX; HIGH THROUGHPUT SCREENING; LRRK2 GENE; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NONHUMAN; PARK2 GENE; PARKINSON DISEASE; PINK1 GENE; PROTEIN PROTEIN INTERACTION; REVIEW; SACCHAROMYCES CEREVISIAE; SINGLE NUCLEOTIDE POLYMORPHISM; SNCA GENE; BIOLOGICAL MODEL; DEGENERATIVE DISEASE; GENETICS; HUMAN; PATHOLOGY;

HUMANS; MODELS, GENETIC; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PATHOLOGY, MOLECULAR; SACCHAROMYCES CEREVISIAE;

EID: 85013224841     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2017.01.013     Document Type: Review

References (105)

1. 1 Skovronsky, D.M., Lee, V.M., Trojanowski, J.Q., Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1 (2006), 151–170.
2. 2 Dobson, C.M., Protein folding and misfolding. Nature 426 (2003), 884–890.
3. 3 Yang, H., Hu, H.Y., Sequestration of cellular interacting partners by protein aggregates: implication in a loss-of-function pathology. FEBS J 283:20 (2016), 3705–3717.
4. 4 Cecchi, C., Stefani, M., The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity. Biophys Chem 182 (2013), 30–43.
5. 5 Gandhi, S., Wood, N.W., Genome-wide association studies: the key to unlocking neurodegeneration?. Nat Neurosci 13 (2010), 789–794.
6. 6 Labbe, C., Lorenzo-Betancor, O., Ross, O.A., Epigenetic regulation in Parkinson's disease. Acta Neuropathol 132:4 (2016), 515–530.
7. 7 Migliore, L., Coppede, F., Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 667 (2009), 82–97.
8. 8 Klein, C., Westenberger, A., Genetics of Parkinson's disease. Cold Spring Harb Perspect Med, 2, 2012, a008888.
9. 9 Spatola, M., Wider, C., Genetics of Parkinson's disease: the yield. Parkinsonism Relat Disord 20:Suppl. 1 (2014), S35–38.
10. 10 Bonifati, V., Genetics of Parkinson's disease—state of the art, 2013. Parkinsonism Relat Disord 20:Suppl. 1 (2014), S23–S28.
11. 11 Yerbury, J.J., Ooi, L., Dillin, A., Saunders, D.N., Hatters, D.M., Beart, P.M., Cashman, N.R., Wilson, M.R., Ecroyd, H., Walking the tightrope: proteostasis and neurodegenerative disease. J Neurochem 137 (2016), 489–505.
12. 12 Lionaki, E., Markaki, M., Palikaras, K., Tavernarakis, N., Mitochondria, autophagy and age-associated neurodegenerative diseases: new insights into a complex interplay. Biochim Biophys Acta 2015 (1847), 1412–1423.
13. 13 Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell 153 (2013), 1194–1217.
14. 14 Bertram, L., Tanzi, R.E., The genetic epidemiology of neurodegenerative disease. J Clin Investig 115 (2005), 1449–1457.
15. 15 Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (New York, N.Y.) 276 (1997), 2045–2047.
16. 16 Hernandez, D.G., Reed, X., Singleton, A.B., Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem, 2016, 10.1111/jnc.13593.
17. 17 Kalinderi, K., Bostantjopoulou, S., Fidani, L., The genetic background of Parkinson's disease: current progress and future prospects. Acta Neurol Scand, 2016, 10.1111/ane.12563.
18. 18 Singleton, A., Hardy, J., The evolution of genetics: Alzheimer's and Parkinson's diseases. Neuron 90 (2016), 1154–1163.
19. 19 Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004), 1167–1169.
20. 20 Singleton, A.B., Farrer, M., Johnson, J., Singleton, a., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, a., Nussbaum, R., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science (New York, N.Y.), 302, 2003, 841.
21. 21 Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J., et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 28 (2013), 811–813.
22. 22 Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A.J., Hardy, J., et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol 125 (2013), 753–769.
23. 23 Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J.T., Schöls, L., Riess, O., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 (1998), 106–108.
24. 24 Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R., et al. G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann Neurol 73 (2013), 459–471.
25. 25 Proukakis, C., Dudzik, C.G., Brier, T., MacKay, D.S., Cooper, J.M., Millhauser, G.L., Houlden, H., Schapira, A.H., A novel α-synuclein missense mutation in Parkinson disease. Neurology 80 (2013), 1062–1064.
26. 26 Zarranz, J.J., Alegre, J., Gómez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55 (2004), 164–173.
27. 27 Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tienari, P.J., Poyhonen, M., Paetau, A., Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging, 35, 2014, 2180 e2181–2185.
28. 28 Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
29. 29 Tofaris, G.K., Spillantini, M.G., Physiological and pathological properties of α-synuclein. Cell Mol Life Sci 64 (2007), 2194–2201.
30. 30 Ross, O.A., Soto-ortolaza, A.I., Heckman, M.G., Jan, O., Abahuni, N., Annesi, G., Bacon, J.A., Bozi, M., Brice, A., Brighina, L., Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study (LRRK2 exonic variants and susceptibility to Parkinson's disease). Lancet Neurol 10 (2011), 898–908.
31. 31 Cookson, M.R., The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11 (2010), 791–797.
32. 32 Rosenbusch, K.E., Kortholt, A., Activation mechanism of LRRK2 and its cellular functions in Parkinson's disease. Parkinsons Dis, 2016, 2016, 7351985.
33. 33•• Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife, 5, 2016 Using a combination of phosphoproteomics, genetics and pharmacology Rab GTPases were identified as LRRK2 targets. LRRK2 was shown to directly induce phosphorylation of these Rab GTPases. Moreover, pathogenic LRvariants altered the Rab GTPase phosphorylation level, which also affected their interaction with several regulatory proteins.
34. 34 Vilarino-Güell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J., Soto-Ortolaza, A.I., Cobb, S.A., Wilhoite, G.J., Bacon, J.A., et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 89 (2011), 162–167.
35. 35 Zimprich, A., Benet-Page, S.A., Struhal, W., Graf, E., Eck, S.H., Offman, M.N., Haubenberger, D., Spielberger, S., Schulte, E.C., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89 (2011), 168–175.
36. 36 Castelo-Branco, G., Wagner, J., Rodriguez, F.J., Kele, J., Sousa, K., Rawal, N., Pasolli, H.A., Fuchs, E., Kitajewski, J., Arenas, E., Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A 100 (2003), 12747–12752.
37. 37 Port, F., Kuster, M., Herr, P., Furger, E., Bänziger, C., Hausmann, G., Basler, K., Wingless secretion promotes and requires retromer-dependent cycling of Wntless. Nat Cell Biol 10 (2008), 178–185.
38. 38 Tabuchi, M., Yanatori, I., Kawai, Y., Kishi, F., Retromer-mediated direct sorting is required for proper endosomal recycling of the mammalian iron transporter DMT1. J Cell Sci 123 (2010), 756–766.
39. 39 Chartier-Harlin, M.C., Dachsel, J.C., Vilariño-Güell, C., Lincoln, S.J., Leprêtre, F., Hulihan, M.M., Kachergus, J., Milnerwood, A.J., Tapia, L., Song, M.S., et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89 (2011), 398–406.
40. 40 Schulte, E.C., Mollenhauer, B., Zimprich, A., Bereznai, B., Lichtner, P., Haubenberger, D., Pirker, W., Brucke, T., Molnar, M.J., Peters, A., et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease. Neurogenetics 13 (2012), 281–285.
41. 41 Nuytemans, K., Bademci, G., Inchausti, V., Dressen, A., Kinnamon, D.D., Mehta, A., Wang, L., Zuchner, S., Beecham, G.W., Martin, E.R., et al. Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology 80 (2013), 982–989.
42. 42 Bonifati, V., Rizzu, P., Squitieri, F., Krieger, E., Vanacore, N., van Swieten, J.C., Brice, A., van Duijn, C.M., Oostra, B., Meco, G., et al. DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24 (2003), 159–160.
43. 43 Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., Shimizu, N., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998), 605–608.
44. 44 Valente, E.M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A.E., Caputo, V., Romito, L., Albanese, A., Dallapiccola, B., Bentivoglio, A.R., PINK1 mutations are associated with sporadic early-onset Parkinsonism. Ann Neurol 56 (2004), 336–341.
45. 45 Narendra, D., Tanaka, A., Suen, D.F., Youle, R.J., Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183 (2008), 795–803.
46. 46 van der Merwe, C., Jalali Sefid Dashti, Z., Christoffels, A., Loos, B., Bardien, S., Evidence for a common biological pathway linking three Parkinson's disease-causing genes: parkin, PINK1 and DJ-1. Eur J Neurosci 41 (2015), 1113–1125.
47. 47 Miller-Fleming, L., Antas, P., Pais, T.F., Smalley, J.L., Giorgini, F., Outeiro, T.F., Yeast DJ-1 superfamily members are required for diauxic-shift reprogramming and cell survival in stationary phase. Proc Natl Acad Sci U S A 111 (2014), 7012–7017.
48. 48•• Lai, Y.C., Kondapalli, C., Lehneck, R., Procter, J.B., Dill, B.D., Woodroof, H.I., Gourlay, R., Peggie, M., Macartney, T.J., Corti, O., et al. Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1. EMBO J 34 (2015), 2840–2861 In their search for novel PINK1-dependent phosphorylation targets, these researchers identified a subfamily of Rab GTPases, that is, Rab8A, 8B and 13, which are phosphorylated by PINK1 activation at the conserved serine 111 residue (Ser111). However, more detailed analysis demonstrated that Rab8A Ser111 is not directly phosphorylated by PINK1. Furthermore, Rab8 phosphorylation at Ser111 disrupts the interaction with its cognate guanine nucleotide exchange factor (GEF), Rabin8, which in turn impairs its activation.
49. 49 Paisa-Ruiz, C., Li, A., Schneider, S.A., Holton, J.L., Johnson, R., Kidd, D., Chataway, J., Bhatia, K.P., Lees, A.J., Hardy, J., et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 33 (2012), 814–823.
50. 50 Park, J.-S., Blair, N.F., Sue, C.M., The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms. Mov Disord 30 (2015), 770–779.
51. 51 Zhao, T., Severijnen, L.-A., van der Weiden, M., Zheng, P., Oostra, B., Hukema, R., Willemsen, R., Kros, J., Md, P., Bonifati, V., FBXO7 immunoreactivity in [alpha]-synuclein-containing inclusions in Parkinson disease and multiple system atrophy. J Neuropathol Exp Neurol 72 (2013), 482–488.
52. 52 Edvardson, S., Cinnamon, Y., Ta-Shma, A., Shaag, A., Yim, Y.I., Zenvirt, S., Jalas, C., Lesage, S., Brice, A., Taraboulos, A., et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One, 7, 2012, e36458.
53. 53 Köroĝlu, Ç., Baysal, L., Cetinkaya, M., Karasoy, H., Tolun, A., DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 19 (2013), 320–324.
54. 54 Krebs, C.E., Karkheiran, S., Powell, J.C., Cao, M., Makarov, V., Darvish, H., Di Paolo, G., Walker, R.H., Shahidi, G.A., Buxbaum, J.D., et al. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum Mutat 34 (2013), 1200–1207.
55. 55 Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G.J., Graafland, J., Wu, B., Xu, F., Erro, R., Amboni, M., et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat 34 (2013), 1208–1215.
56. 56 Setó-Salvia, N., Clarimón, J., Pagonabarraga, J., Pascual-Sedano, B., Campolongo, A., Combarros, O., Mateo, J.I., Regaña, D., Martínez-Corral, M., Marquié, M., et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 68 (2011), 359–364.
57. 57 Sidransky, E., Lopez, G., The link between the GBA gene and parkinsonism. Lancet Neurol 11 (2012), 986–998.
58. 58 Falkenburger, B.H., Saridaki, T., Dinter, E., Cellular models for Parkinson's disease. J Neurochem, 2016.
59. 59 Alberio, T., Lopiano, L., Fasano, M., Cellular models to investigate biochemical pathways in Parkinson's disease. FEBS J 279 (2012), 1146–1155.
60. 60• Soria-Valles, C., Lopez-Otin, C., iPSCs: on the road to reprogramming aging. Trends Mol Med 22 (2016), 713–724 This review focuses on the different applications of induced pluripotent stem cells (iPSCs) for modelling age-related human disorders such as progeriod syndromes and the neurodegenerative diseases Alzheimer's and Parkinson's. Besides an overview of the available human iPSC models for these diseases, the authors also discuss the potential to use iPSCs in regenerative medicine and their use in drug screening for the identification of novel therapeutic targets.
61. 61 Harrington, A.J., Hamamichi, S., Caldwell, G.A., Caldwell, K.A., C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. Dev Dyn 239 (2010), 1282–1295.
62. 62• Sin, O., Michels, H., Nollen, E.A., Genetic screens in Caenorhabditis elegans models for neurodegenerative diseases. Biochim Biophys Acta 1842 (2014), 1951–1959 This review describes humanized C. elegans models for polyglutamine diseases, Parkinson's and Alzheimer's disease. These models recapitulate faithfully some important aspects of these diseases such as protein aggregation and toxicity. Furthermore, genetic screens performed in the nematod models have been very instrumental in dissecting the mechanisms involved in the development of neurodegenerative disorders.
63. 63 Chen, X., Barclay, J.W., Burgoyne, R.D., Morgan, A., Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases. Chem Cent J, 9, 2015, 65.
64. 64 Whitworth, A.J., Drosophila models of Parkinson's disease. Adv Genet 73 (2011), 1–50.
65. 65 Lee, Y., Dawson, V.L., Dawson, T.M., Animal models of Parkinson's disease: vertebrate genetics. Cold Spring Harb Perspect Med, 2, 2012.
66. 66 Tieu, K., A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med, 1, 2011, a009316.
67. 67• Johnson, I.P., Age-related neurodegenerative disease research needs aging models. Front Aging Neurosci, 7, 2015, 168 This opinion article highlights the relevance of using aging experimental models in age-related neurodegenerative disease research.
68. 68 Wallace, L.M., Howlett, S.E., Commentary: age-related neurodegenerative disease research needs aging models. Front Aging Neurosci, 8, 2016, 9.
69. 69• Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., Baekelandt, V., alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522 (2015), 340–344 To investigate the different in vivo properties of α-Synuclein (aSyn) assemblies, aSyn oligomers, fibrils and ribbons were injected in rat brain. This revealed that fibrils are the most toxic strain leading to synaptic impairment and cell death. Additionally, it was shown that propagation of aSyn assemblies is strain dependent and aSyn assemblies are able to cross the blood–brain barrier.
70. 70 Rey, N.L., Steiner, J.A., Maroof, N., Luk, K.C., Madaj, Z., Trojanowski, J.Q., Lee, V.M., Brundin, P., Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med 213 (2016), 1759–1778.
71. 71 Khurana, V., Lindquist, S., Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast?. Nat Rev Neurosci 11 (2010), 436–449.
72. 72 Outeiro, T.F., Lindquist, S., Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302 (2003), 1772–1775.
73. 73 Buttner, S., Bitto, A., Ring, J., Augsten, M., Zabrocki, P., Eisenberg, T., Jungwirth, H., Hutter, S., Carmona-Gutierrez, D., Kroemer, G., et al. Functional mitochondria are required for alpha-synuclein toxicity in aging yeast. J Biol Chem 283 (2008), 7554–7560.
74. 74 Su, L.J., Auluck, P.K., Outeiro, T.F., Yeger-Lotem, E., Kritzer, J.A., Tardiff, D.F., Strathearn, K.E., Liu, F., Cao, S., Hamamichi, S., et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 3 (2010), 194–208.
75. 75 Buttner, S., Habernig, L., Broeskamp, F., Ruli, D., Vogtle, F.N., Vlachos, M., Macchi, F., Kuttner, V., Carmona-Gutierrez, D., Eisenberg, T., et al. Endonuclease G mediates alpha-synuclein cytotoxicity during Parkinson's disease. EMBO J 32 (2013), 3041–3054.
76. 76 Rostovtseva, T.K., Gurnev, P.A., Protchenko, O., Hoogerheide, D.P., Yap, T.L., Philpott, C.C., Lee, J.C., Bezrukov, S.M., alpha-Synuclein shows high affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease. J Biol Chem 290 (2015), 18467–18477.
77. 77 Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H., Zweckstetter, M., Outeiro, T.F., Braus, G.H., Aggregate clearance of alpha-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J Biol Chem 287 (2012), 27567–27579.
78. 78 Sampaio-Marques, B., Felgueiras, C., Silva, A., Rodrigues, M., Tenreiro, S., Franssens, V., Reichert, A.S., Outeiro, T.F., Winderickx, J., Ludovico, P., SNCA (alpha-synuclein)-induced toxicity in yeast cells is dependent on sirtuin 2 (Sir2)-mediated mitophagy. Autophagy 8 (2012), 1494–1509.
79. 79 Sharma, N., Brandis, K.A., Herrera, S.K., Johnson, B.E., Vaidya, T., Shrestha, R., Debburman, S.K., alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J Mol Neurosci 28 (2006), 161–178.
80. 80 Witt, S.N., Flower, T.R., alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease. FEMS Yeast Res 6 (2006), 1107–1116.
81. 81 Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 (2006), 324–328.
82. 82 Zabrocki, P., Bastiaens, I., Delay, C., Bammens, T., Ghillebert, R., Pellens, K., De Virgilio, C., Van Leuven, F., Winderickx, J., Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim Biophys Acta 1783 (2008), 1767–1780.
83. 83 Sancenon, V., Lee, S.A., Patrick, C., Griffith, J., Paulino, A., Outeiro, T.F., Reggiori, F., Masliah, E., Muchowski, P.J., Suppression of alpha-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. Hum Mol Genet 21 (2012), 2432–2449.
84. 84• Tenreiro, S., Reimao-Pinto, M.M., Antas, P., Rino, J., Wawrzycka, D., Macedo, D., Rosado-Ramos, R., Amen, T., Waiss, M., Magalhaes, F., et al. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet, 10, 2014, e1004302 Using yeast cells expressing human aSyn it is demontrated that bloking phosphorylation at S129 alteres the degradation fate of aSyn impairing its degradation via autophagy, increasing inclusions formation and toxicity.
85. 85 Popova, B., Kleinknecht, A., Braus, G.H., Posttranslational modifications and clearing of alpha-synuclein aggregates in yeast. Biomolecules 5 (2015), 617–634.
86. 86 Shahpasandzadeh, H., Popova, B., Kleinknecht, A., Fraser, P.E., Outeiro, T.F., Braus, G.H., Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions. J Biol Chem 289 (2014), 31224–31240.
87. 87• Tenreiro, S., Rosado-Ramos, R., Gerhardt, E., Favretto, F., Magalhaes, F., Popova, B., Becker, S., Zweckstetter, M., Braus, G.H., Outeiro, T.F., Yeast reveals similar molecular mechanisms underlying alpha- and beta-synuclein toxicity. Hum Mol Genet 25 (2016), 275–290 Expressing human beta-synuclein (bSyn) in yeast, it was observed that bSyn also forms inclusions and is toxic for yeast cells and shares similar toxicity mechanisms with aSyn, including vesicular trafficking impairment and induction of oxidative stress. Moreover, bSyn forms heterodimers with aSyn in yeast and in human cells.
88. 88 Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M., Moore, D.J., GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet, 6, 2010, e1000902.
89. 2 stress depending on mitochondrial function and endocytosis in a yeast model. Biochim Biophys Acta 1840 (2014), 2025–2031 Using a yeast model, authors described LRRK2 confers cellular protection during oxidative stress depending on mitochondrial function and endocytosis, indicating that these can represent intersecting pathways in the LRRK2 function.
90. 90 Pereira, C., Costa, V., Martins, L.M., Saraiva, L., A yeast model of the Parkinson's disease-associated protein Parkin. Exp Cell Res 333 (2015), 73–79.
91. 91 Zondler, L., Miller-Fleming, L., Repici, M., Goncalves, S., Tenreiro, S., Rosado-Ramos, R., Betzer, C., Straatman, K.R., Jensen, P.H., Giorgini, F., et al. DJ-1 interactions with alpha-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. Cell Death Dis, 5, 2014, e1350.
92. 92 Giaever, G., Chu, A.M., Ni, L., Connelly, C., Riles, L., Veronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., Andre, B., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418 (2002), 387–391.
93. 93 Winzeler, E.A., Shoemaker, D.D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J.D., Bussey, H., et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285 (1999), 901–906.
94. 94 Gitler, A.D., Chesi, A., Geddie, M.L., Strathearn, K.E., Hamamichi, S., Hill, K.J., Caldwell, K.A., Caldwell, G.A., Cooper, A.A., Rochet, J.C., et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41 (2009), 308–315.
95. 95 Liang, J., Clark-Dixon, C., Wang, S., Flower, T.R., Williams-Hart, T., Zweig, R., Robinson, L.C., Tatchell, K., Witt, S.N., Novel suppressors of alpha-synuclein toxicity identified using yeast. Hum Mol Genet 17 (2008), 3784–3795.
96. 96 Willingham, S., Outeiro, T.F., DeVit, M.J., Lindquist, S.L., Muchowski, P.J., Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302 (2003), 1769–1772.
97. 97 Flower, T.R., Clark-Dixon, C., Metoyer, C., Yang, H., Shi, R., Zhang, Z., Witt, S.N., YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. J Cell Biol 177 (2007), 1091–1104.
98. 98 Dhungel, N., Eleuteri, S., Li, L.B., Kramer, N.J., Chartron, J.W., Spencer, B., Kosberg, K., Fields, J.A., Stafa, K., Adame, A., et al. Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on alpha-synuclein. Neuron 85 (2015), 76–87.
99. 99 Xiong, Y., Yuan, C., Chen, R., Dawson, T.M., Dawson, V.L., ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci 32 (2012), 3877–3886.
100. 100 Buttner, S., Delay, C., Franssens, V., Bammens, T., Ruli, D., Zaunschirm, S., de Oliveira, R.M., Outeiro, T.F., Madeo, F., Buee, L., et al. Synphilin-1 enhances alpha-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent manner. PLoS One, 5, 2010, e13700.
101. 101•• Zhao, L., Yang, Q., Zheng, J., Zhu, X., Hao, X., Song, J., Lebacq, T., Franssens, V., Winderickx, J., Nystrom, T., et al. A genome-wide imaging-based screening to identify genes involved in synphilin-1 inclusion formation in Saccharomyces cerevisiae. Sci Rep, 6, 2016, 30134 Using yeast cells expressing human synphilin-1, authors identified the interaction networks and components involved in the formation of synphilin-1 inclusions. Evidence is given that synphilin-1 inclusion formation has a cytoprotective effect to the cell.
102. 102 Tardiff, D.F., Lindquist, S., Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease. Drug Discov Today Technol 10 (2013), e121–128.
103. 103 Griffioen, G., Duhamel, H., Van Damme, N., Pellens, K., Zabrocki, P., Pannecouque, C., van Leuven, F., Winderickx, J., Wera, S., A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta 1762 (2006), 312–318.
104. 104 Kritzer, J.A., Hamamichi, S., McCaffery, J.M., Santagata, S., Naumann, T.A., Caldwell, K.A., Caldwell, G.A., Lindquist, S., Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol 5 (2009), 655–663.
105. 105 Tardiff, D.F., Jui, N.T., Khurana, V., Tambe, M.A., Thompson, M.L., Chung, C.Y., Kamadurai, H.B., Kim, H.T., Lancaster, A.K., Caldwell, K.A., et al. Yeast reveal a “druggable” Rsp5/Nedd4 network that ameliorates alpha-synuclein toxicity in neurons. Science 342 (2013), 979–983.